Mirtazapin Aristo (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Aristo, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and is available under EU marketing authorization for use under medical supervision.

GNH USA supplies Mirtazapin Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across EU and other markets. Our distribution network ensures timely delivery and compliance with local import regulations.

Mirtazapine acts on central neurotransmitter pathways to alleviate depressive symptoms and is indicated for the following conditions: - Major depressive disorder: reduces depressive mood, improves energy and interest in daily activities. - Depressive episodes in bipolar disorder (adjunct): helps alleviate depressive symptoms when used alongside mood stabilizers. - Depression with insomnia: improves sleep quality while treating depressive symptoms.

Mirtazapine may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Sedation - Increased appetite - Weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis - Neutropenia - Severe hypersensitivity reactions - Suicidal thoughts or behavior - Hepatic dysfunction - Seizures

When prescribing mirtazapine, clinicians should observe several safety considerations. - Monitor weight: patients may experience increased appetite and weight gain, requiring periodic assessment. - Assess for suicidal ideation: initiate close observation during early treatment, especially in younger adults. - Evaluate hepatic function: use with caution in patients with liver impairment and adjust if necessary. - Review concomitant CNS depressants: combined use may enhance sedation and respiratory depression. - Avoid abrupt discontinuation: taper the dose gradually to reduce risk of withdrawal symptoms. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate serotonin syndrome; a washout period is required. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma concentrations, raising toxicity risk. - Other serotonergic agents (e.g., tramadol, triptans): heighten the chance of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CNS depressants (alcohol, benzodiazepines, antihistamines): may intensify sedation and impair psychomotor performance. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): can reduce mirtazapine levels, potentially diminishing therapeutic effect. - SSRIs or SNRIs: combined use may increase serotonergic side effects; monitor for agitation or hyponatremia.